{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:56:45Z","timestamp":1771678605285,"version":"3.50.1"},"reference-count":38,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1080\/13543784.2024.2313091","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T08:29:11Z","timestamp":1708331351000},"page":"127-132","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["The impact of current investigational drugs for acne on future treatment strategies"],"prefix":"10.1080","volume":"33","author":[{"given":"Heli A.","family":"Patel","sequence":"first","affiliation":[{"name":"Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Guo","sequence":"additional","affiliation":[{"name":"Rosalind Franklin University of Medicine and Science Chicago Medical School, North Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA"},{"name":"Wake Forest School of Medicine, Dermatology, Pathology, and Public Health Sciences, Winston-Salem, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.078"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.618"},{"issue":"12","key":"e_1_3_4_5_1","first-page":"892","article-title":"Acne in adolescents","volume":"46","author":"Gebauer K.","year":"2017","unstructured":"Gebauer K. Acne in adolescents. Aust Fam Physician. 2017;46(12):892\u2013895.","journal-title":"Aust Fam Physician"},{"issue":"2","key":"e_1_3_4_6_1","first-page":"97","article-title":"Prevalence and risk factors of acne scarring among patients consulting dermatologists in the USA","volume":"16","author":"Tan J","year":"2017","unstructured":"Tan J, Kang S, Leyden J. Prevalence and risk factors of acne scarring among patients consulting dermatologists in the USA. J Drugs Dermatol. 2017;16(2):97\u2013102.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12149"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1584182"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00542-y"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1337745"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21739"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920106779116928"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25173935"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2017.1381087"},{"key":"e_1_3_4_15_1","unstructured":"Sagimet Biosciences Inc. Study Of TVB-2640 In Subjects With Nonalcoholic Steatohepatitis (NASH). ClinicalTrials.gov Identifier: NCT04906421. 2021 May. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04906421?term=FASCINATE-2&draw=2&rank=1."},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0245-x"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0465"},{"issue":"5","key":"e_1_3_4_18_1","first-page":"412","article-title":"Cortexolone 17\u03b1-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro","volume":"18","author":"Rosette C","year":"2019","unstructured":"Rosette C, FJ A, Mazzetti A, et al. Cortexolone 17\u03b1-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412\u2013418.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00666-9"},{"issue":"6","key":"e_1_3_4_20_1","first-page":"563","article-title":"Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study","volume":"18","author":"Mazzetti A","year":"2019","unstructured":"Mazzetti A, Moro L, Gerloni M, et al. Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study. J Drugs Dermatol. 2019;18(6):563.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0464"},{"key":"e_1_3_4_22_1","unstructured":"Suzhou Kintor Pharmaceutical Inc. A Randomized Double-Blind Placebo-Controlled Parallel Group Dose Escalation Study In Subjects To Evaluate The Safety Tolerability And Pharmacokinetics Of GT20029 Following Topical Single And Multiple Ascending Dose Administration. ClinicalTrials.gov Identifier: NCT05428449. [cited 2022 Jun 23]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05428449."},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.05.032"},{"key":"e_1_3_4_24_1","unstructured":"Ivezic-Schoenfeld Z. A phase I multi-center double-blind randomized dose escalating Parallel Group placebo-controlled safety tolerability and immunogenicity study of ORI-A-ce001 for the treatment of facial acne vulgaris. ClinicalTrials.gov Identifier: NCT05131373. 2022 Jul 11. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05131373."},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1139\/o06-044"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13607"},{"key":"e_1_3_4_27_1","unstructured":"Lim J. (2021 Dec). A Randomized Double-Blind Placebo-Controlled Trial To Determine The Safety And Efficacy Of Lactoferrin With Vitamin E And Zinc As An Oral Therapy For Mild To Moderate Hormonal Acne In Adult Women. Identifier NCT05151055. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05151055."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/14767058.2015.1049149"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1139\/o06-040"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2067819"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00587-5"},{"key":"e_1_3_4_32_1","volume-title":"A phase 2, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of imsidolimab (ANB019) in the treatment of subjects with acne vulgaris","author":"AnaptysBio, Inc","year":"2021","unstructured":"AnaptysBio, Inc. A phase 2, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of imsidolimab (ANB019) in the treatment of subjects with acne vulgaris. 2021 September ClinicalTrials.gov Identifier: NCT04856917. 2021 Apr. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04856917"},{"key":"e_1_3_4_33_1","volume-title":"A study of tolerability, safety, and efficacy, of DMT310 in patients with acne vulgaris","author":"Dermata Therapeutics","year":"2018","unstructured":"Dermata Therapeutics. A study of tolerability, safety, and efficacy, of DMT310 in patients with acne vulgaris. 2020 JuneClinicalTrials.gov Identifier: NCT03536637. 2018 May. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03536637"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.21"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00023-15"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041480"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00003-13"},{"key":"e_1_3_4_38_1","unstructured":"Taylor E (2018 Jan \u2013 2020 Aug). A Phase 1B Dose Escalating Study Of The Safety Short-Term Engraftment And Action Of a Singly-Applied NB01 In Adults With Moderate Acne. ClinicalTrials.gov Identifier: NCT03450369. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03450369"},{"key":"e_1_3_4_39_1","unstructured":"Mohamed Awad S (2019 Sep \u2013 2022 Nov). The Topical Preparations Are Packed In Non-Identifiable Jars And Coded By a Person Who Is Not Involved In The Study The Patient. ClinicalTrials.gov Identifier: NCT04080869. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04080869"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2024.2313091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T18:37:09Z","timestamp":1727203029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2024.2313091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1080\/13543784.2024.2313091"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2024.2313091","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}